Batiza Resendiz Víctor Alfonso¹*, Aguilar Melgar Ashanti², Luna Rojas Rosa Martha³, Pérez-Peña Efraín⁴, Gutiérrez Gutiérrez Antonio⁵, Ruvalcaba Castrellón Luis Arturo⁶, Salazar López-Ortiz Carlos⁷, Michel Vergara Jorge Alejandro⁸, Shaw Dulin Robin Jennifer⁹, Barquet Muñoz Salim Abraham⁹, Hernández López Luis Arturo¹⁰, García Rodríguez Francisco José¹¹, Cortés Esteban Patricia¹², Sánchez Llamas Benito¹³, Rodríguez Calderóon Ricardo¹⁴ and Maldonado Rosas Israel¹⁵

¹Gynecology and Reproductive Biology, General Coordinator of the Consensus, Fertility, Monterrey, N.L., Mexico
²Gynecology and Reproductive Biology, Associate Coordinator, IECH Monterrey, Mexico
³Gynecology and Biology of Reproduction, RMA of New York Mexico, Mexico City, Mexico
⁴Gynecology and Reproductive Biology, LIFE Institute, Guadalajara Jalisco, Mexico
⁵Gynecology and Reproductive Biology, LIFE Institute, Leon, Guanajuato, Mexico
⁸Gynecology and Reproductive Biology, Mexican Institute of Infertility, Guadalajara Jalisco, Mexico
⁷Biology of Reproduction, Spanish Hospital, HISPAREP Assisted Reproduction Clinic, Mexico City, Mexico
⁸Biology of Reproduction, CEFERTIL Fertility Center, Guadalajara Jalisco, Mexico
⁹Gynecology Oncology, National Cancer Institute, Mexico City, Mexico
¹⁰Gynecology Oncology, National Cancer Institute, National Institute of Perinatology, Mexico City, Mexico
¹¹Oncological Surgery, Spanish Hospital, Mexico City, Mexico
¹²Gynecology and Obstetrics, Oncology, November 20 National Medical Center Hospital, ISSSTE, Mexico City, Mexico
¹³Internal Medicine, Medical Oncology, Guadalajara Jalisco, Mexico
¹⁴Embryology, Spanish Hospital, HISPAREP Assisted Reproduction Clinic, Mexico City, Mexico
¹⁵Embryology, Assisted Reproduction Center CITMER, Mexico

*Corresponding Author: Batiza Resendiz Víctor Alfonso, Gynecology and Reproductive Biology, General Coordinator of the Consensus, Fertility, Monterrey, N.L., Mexico.

Received: June 17, 2022; Published: March 31, 2023

Abstract

Fertility preservation is the application of medical and laboratory strategies to preserve parental genetic offspring in adults or children at risk of sterility.

Cancer is the main indication of fertility preservation in patients of reproductive age. In recent decades, the incidence of cancer in adolescents has increased. Cancer treatments have also improved significantly, making cure possible today in a large percentage of patients. Most children and adolescents with cancer become long-term survivors, increasing interest in the effects of cancer treatment on fertility.

Social, economic and cultural conditions are also decisive in deciding when a couple seeks to promote their fertility.

Furthermore, other pathologies or even drugs for the prevention of rejection of transplanted organs can affect fertility and, therefore, such patients are susceptible to guidance on fertility preservation.

Success in assisted reproduction programs and cancer treatments provide alternatives to preserve fertility.

In this first Opinion of the Group of Mexican Experts on Fertility Preservation, we have evaluated oncological patients who are candidates for fertility preservation: young people at risk of compromising their fertility due to oncological treatment, but with sufficient ovarian reserve and acceptable vital prognosis. Special cases such as social preservation were also considered, in cases of different sexual conceptualization, as well as the basic legal and ethical aspects.

Keywords: Fertility Preservation; Cancer Treatment; Cryopreservation; Freezing; Oocyte; Ovarian Tissue Transplantation; Cancer Survivorship; Gonadotoxicity; Premature Gonadal Failure

References

1. Pesce R., et al. “Preservación de la fertilidad”. Reproducción 2 (2017): 34-39.
2. Bray F., et al. “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries”. GLOBOCAN CA: A Cancer Journal for Clinicians6 (2018): 394-424.
3. Taylan E and Oktay K. “Fertility preservation in gynecologic cancers”. Gynecologic Oncology3 (2019): 522-529.
4. Peccatori FA., et al. “Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”. Annals of OncologyS6 (2013): 160-170.
5. Cetina-Pérez L., et al. “Consensus Reporton the Prevention, Diagnosis, and Treatment of Cervical Cancer-a Perspective from the Immune System Toward Immunotherapy”. Revista de Investigación Clínica3 (2020).
6. Neerja B., et al. “FIGO CANCER REPORT 2018. Cancer of the cervix uteri”. International Journal of Gynecology and ObstetricsS2 (2018): 22-36.
7. National Comprehensive Cancer Network Guidelines Version 4.2019. Cervical Cancer. NCCN Evidence Blocks (2019).
8. Koh W-J., et al. “Cervical cancer”. In: Journal of the National Comprehensive Cancer Network : JNCCN 11 (2013): 320-343.
9. Benedetti Panici P., et al. “Pelvic and aortic lymphadenectomy in cervical cáncer: The standardization of surgical procedure and its clinical impact”. Gynecologic Oncology 113 (2009): 284-290.
10. Egner JR. “AJCC Cancer Staging Manual”. JAMA 304 (2010): 1726.
11. Delgado G., et al. “Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: A gynecologic oncology group study”. In: Gynecologic Oncology 38 (1990): 352-357.
12. Lea JS and Lin KY. “Cervical Cancer”. Obstetrics and Gynecology Clinics of North America 39 (2012): 233-253.
13. Alammari RA., et al. “Impact of prior hysterectomy on surgical outcomes for laparoscopic adnexal surgery”. Surgical Endoscopy 7 (2020): 2980-2986.
14. Chemaitilly W., et al. “Acute ovarian failure in the childhood cancer survivor study”. The Journal of Clinical Endocrinology and Metabolism5 (2006): 1723-1728.
15. Wo Jennifer Y and Viswanathan Akila N. “The impact of radio therapy on fertility, pregnancy, and neonatal outcomes of female cancer patients”. International Journal of Radiation Oncology - Biology - Physics 73 (2009): 1304-1312.
16. Signorello LB., et al. “Female Survivors of Childhood Cancer: Preterm Birth and Low Birth Weight Among Their Children”. Journal of the National Cancer Institute 20 (2006): 1453-1461.
17. De Felice F., et al. “Fertility preservation in gynaecologic cancers”. Ecancermedicalscience 12 (2018): 798.
18. Agarwal S., et al. “Outcomes of patients undergoing radical hysterectomy for cervical cancer of high-risk histological subtypes”. International Journal of Gynecological Cancer1 (2011): 123-127.
19. Hricak H., et al. “Role of imaging in pretreatment evaluation of early invasive cervical cancer: results of the intergroup study American College of Radiology Imaging Network 6651-Gynecologic Oncology Group 183”. Journal of Clinical Oncology36 (2005): 9329-9337.
20. Zhang W., et al. “Impact of pelvic MRI in routine clinical practice on staging of IB1-IIA2 cervical cancer”. Cancer Managements Methods 11 (2019): 3603-3609.
21. Selman TJ., et al. “Diagnostic accuracy of tests for lymph node status in primary cervical cancer: a systematic review and meta-analysis”. CMAJ 7 (2008): 855-862.
22. Willows K., et al. “Fertility-sparing management in cervical cancer: balancing oncologic outcomes with reproductive success”. Gynecologic Oncology Research and Practice 3 (2016): 9.
23. Gubbala K., et al. “Outcomes of ovarian transposition in gynaecological cancers; a systematic review and meta-analysis”. Journal of Ovarian Research 7 (2014): 69.
24. Gómez-Pue D., et al. “Tratamiento preservador de la fertilidad en adenocarcinoma de endometrio”. Ginecologia y obstetricia de Mexico 10 (2011): 631-636.
25. Ruvalcaba-Limón E., et al. “Primer Consenso Mexicano de Cáncer de Endometrio Grupo de Investigación en Cáncer de Ovario y Tumores Ginecológicos de México “GICOM”. Revista de Investigación Clínica6 (2010): 585-605.
26. Gupta JK., et al. “Ultrasonographic endometrial thickness for diagnosing endometrial pathology in women with postmenopausal bleeding: a meta-analysis”. Acta Obstetricia et Gynecologica Scandinavica9 (2002): 799.
27. Clark TJ., et al. “Accuracy of outpatient endometrial biopsy in the diagnosis of endometrial cancer: a systematic, quantitative review”. BJOG3 (2002): 313.
28. Soslow RA., et al. “Endometrial Carcinoma Diagnosis: Use of FIGO Grading and Genomic Subcategories in Clinical Practice: Recommendations of the International Society of Gynecological Pathologists”. International Journal of Gynecological Pathology 38 (2019): S64-S74.
29. Schenker JG. “Report of the FIGO Committee for the Study of Ethical Aspects of Human Reproduction. International Federation of Gynecology and Obstetrics”. International Journal of Gynecology and Obstetrics 1 (1997): 95-99.
30. Park JY. “Hysteroscopy in fertility-sparing management for early endometrial cancer: a double-edged sword”. Journal of Gynecologic Oncology1 (2017): e16.
31. Rizzo S., et al. “Endometrial cancer: an overview of novelties in treatment and related imaging keypoints for local staging”. Cancer Imaging1 (2019): 45.
32. Ushijima K. “Fertility sparing treatment for early stage endometrial cancer: current situation and new strategy”. Journal of Gynecologic Oncology6 (2019): e117.
33. Park JY and Nam JH. “Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer”. Oncologist 3 (2015): 270-278.
34. Kalogiannidis I and Agorastos T. “Conservative management of young patients with endometrial highly-differentiated adenocarcinoma”. Journal of Obstetrics and Gynaecology1 (2011): 13-17.
35. Wei J., et al. “Comparison of fertility-sparing treatments in patients with early endometrial cancer and atypical complex hyperplasia: A meta-analysis and systematic review”. Medicine (Baltimore)37 (2019): e8034.
36. Mendonça Carneiro M., et al. “Fertility-preservation in endometrial cancer: is it safe? Review of the literature”. JBRA Assisted Reproduction 4 (2016): 232-239.
37. Lu KH., et al. “Endometrial and ovarian cancer in women with Lynch syndrome: update in screening and prevention”. Fam Cancer2 (2013): 273-277.
38. TopfedaisiOzkan N., et al. “Factors associated with survival after relapse in patients with low-risk endometrial cancer treated with surgery alone”. Journal of Gynecologic Oncology5 (2017): e65.
39. Zhao J., et al. “Does ovarian stimulation for IVF increase gynaecological cancer risk? A systematic review and meta-analysis”. Reproductive BioMedicine Online 1 (2015): 20-29.
40. Dahhana T., et al. “Stimulation of the ovaries in women with breast cancer undergoing fertility preservation: Alternative versus standard stimulation protocols; the study protocol of the STIM-trial”. Contemporary Clinical Trials 61 (2017): 96-100.
41. Conghui Liu., et al. “Double ovarian stimulation during the follicular and luteal phase in women ≥38 years: a retrospective case-control study”. Reproductive BioMedicine Online 6 (2017): 678-684.
42. Mintziori G and Goulis DG. “In vitro fertilization/intracytoplasmic insemination and thyroid function: reviewing the evidence”. Metabolism 86 (2018): 44-48.
43. Torpy JM., et al. “Ovarian Cancer”. JAMA23 (2011): 2484.
44. Buys SS., et al. “Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial”. JAMA 305 (2011): 2295-2303.
45. Kobayashi H., et al. “A randomized study of screening for ovarian cancer: a multicenter study in Japan”. International Journal of Gynecological Cancer 18 (2008): 414-420.
46. Fischerova D., et al. “Diagnosis, Treatment, and Follow-Up of Borderline Ovarian Tumors”. Oncologist 12 (2012): 1515-1533.
47. Lhereux S., et al. “Ephitelial Ovarian Cancer: evolution of management in the era of precisión medicine”. CA: A Cancer Journal for Clinicians 69 (2019): 280-304.
48. Lisio MA., et al. “High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints”. International Journal of Molecular Sciences 4 (2019): 952.
49. Shaaban AM., et al. “Ovarian malignant germ cell tumors: cellular classification and clinical and imaging features”. Radiographics3 (2014): 777-801.
50. Prat J. “The results of conservative (fertility-sparing) treatment in borderline ovarian tumors vary depending on age and histological type”. Annals of Oncology7 (2014): 1255-1258.
51. Schultz KA., et al. “Ovarian Sex Cord-Stromal Tumors”. JCO Oncology Practice 10 (2016): 940-946.
52. Khosla D., et al. “Ovarian granulosa cell tumor: clinical features, treatment, outcome, and prognostic factors”. North American Journal of Medical Sciences 3 (2014): 133-138.
53. Mangili G., et al. “Long-term follow-up is crucial after treatment for granulosa cell tumours of the ovary”. British Journal of Cancer 109 (2013): 29-34.
54. Robboy SJ., et al. “Robboy's Pathology of the Female Reproductive Tract”. 2^nd Edinburgh: Churchill Livingstone (2008).
55. Kurman RJ. “Blaustein's Pathology of the Female Genital Tract”. 5^th New York: Springer (2002).
56. Gui T., et al. “A clinicopathological analysis of 40 cases of ovarian Sertoli-Leydig cell tumors”. Gynecologic Oncology2 (2012): 384-389.
57. SSA, Consejo Nacional de Población. Consenso Mexicano sobre diagnóstico y tratamiento del cáncer mamario. Octava revisión. Colima (2019).
58. Soto-Estrada G., et al. Revista de la Facultad de Medicina (Méx.) 59.6 (2016): 8-22.
59. Amin MB., et al. “AJCC Cancer Staging Manual”. 8^th Switzerland: Springer, (2017).
60. Pagani O., et al. “POSITIVE: A study evaluating Pregnancy, disease outcome and safety of interrupting endocrine therapy for premenopausal women with endocrine responsive breast cancer who desire pregnancy (IBCSG 48-14/BIG 8-13)”. Cancer ResearchS4 (2019): OT1-01-06.
61. Dolmans M-M., et al. “European recommendations for female fertility preservation (EU-REFER): a joint collaboration between oncologists and fertility specialists”. Critical Reviews in Oncology/Hematology 138 (2019): 233-240.
62. Donnez J and Dolmans MM. “Fertility preservation in women”. NEJM 377 (2017): 1657-1665.
63. Cakman H., et al. “Effective method for emergency fertility preservation: random-start controlled ovarian stimulation”. Fertility and Sterility6 (2013): 1673-1680.
64. Abdel-Razeq H. “Gonadotropin-releasing hormone agonists during chemotherapy for ovarian function and fertility preservation for patients with early-stage breast cancer”. Cancer Management and Research 11 (2019): 4273-4282.
65. Siegel RL., et al. “Cancer statistics, 2019”. CA: A Cancer Journal for Clinicians1 (2019): 7-34.
66. Noone AM., et al. “SEER Cáncer Statistics Review, 1975-2015”. National Cáncer Institute (2018).
67. General Adjunta de Epidemiología. Registro de Cáncer en Niños y Adolescentes. Sistema EstadísticoEpidemiológico de las Defunciones. censia.salud.gob.mx (2015).
68. Johnson EK., et al. “Fertility Preservation for Pediatric Patients: Current State and Future Possibilities”. Journal of Urology 198 (2017): 186-194.
69. Levine J., et al. “Fertility preservation in adolescents and young adults with cancer”. Journal of Clinical Oncology 28 (2010): 4831-4841.
70. Hudson MM. MD. “Reproductive Outcomes for Survivors of Childhood Cancer”. Obstetrics and Gynaecology5 (2010): 1171-1183.
71. Coccia PF., et al. JNCCN1 (2018): 66-97.
72. Barton SE., et al. “Infertility, infertility treatment, and achievement of pregnancy in female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort”. Lancet Oncology9 (2019): 873-881.
73. Green DM., et al. “Fertility of female survivors of childhood cancer: a report from the childhood cancer survivor study”. Journal of Clinical Oncology16 (2006): 2677-2685.
74. Huddart RA., et al. “Fertility, gonadal and sexual function in survivors of testicular cancer”. British Journal of Cancer 2 (2005): 200-207.
75. Tangir J., et al. “Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary”. Obstetrics and Gynaecology2 (2003): 251-257.
76. Carling T and Udelsman R. “Thyroid tumors”. In: DeVita VT Jr, Lawrence TS, Rosenberg SA: Cancer: Principles and Practice of Oncology. 9^th Philadelphia, Pa: Lippincott Williams and Wilkins, (2011): 1457-1472.
77. Nelson H., et al. “Guidelines 2000 for colon and rectal cancer surgery”. Journal of the National Cancer Institute 8 (2001): 583-596.
78. Ries LAG., et al. “Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995”. National Cancer Institute, SEER Program. NIH Pub. (1999).
79. Swerdlow SH., et al. “The 2016 revision of the World Health Organization classification of lymphoid neoplasms”. Blood20 (2016): 2375-2390.
80. Smith MA., et al. “Declining childhood and adolescent cancer mortality”. Cancer16 (2014): 2497-2506.
81. González-Ortega C., et al. “Natural cycle in vitro fertilization (IVF) combined with in vitro maturation in infertile patients with polycystic ovarian syndrome (PCOS) requiring IVF”. TJOG 80 (2019): 192-195.
82. Zhang J. “Luteal phase ovarian stimulation following oocyte retrieval is it helpful for poor responders”. Reproductive Biology and Endocrinology 13 (2015): 76.
83. Adams GP., et al. “Large animal models for the study of ovarian follicular dynamics in wo men”. Theriogenology 78 (2012): 1733-1748.
84. Kim JH., et al. “Efficacy of Random-start Controlled Ovarian Stimulation in Cancer Patients”. Journal of Korean Medical Science 3 (2015): 290-295.
85. Ubaldi FM., et al. “Follicular versus luteal phase ovarian stimulation during the same menstrual cycle (DuoStim) in a reduced ovarian reserve population results in a similar euploid blastocyst formation rate: new insight in ovarian reserve exploitation”. Fertility and Sterility 105 (2016): 1488-1495.
86. Tsampras N., et al. “Double ovarian stimulation (Duostim) protocol for fertility preservation in female oncology patients”. Human Fertility4 (2017): 248-253.
87. Shah DK., et al. “Medical, ethical and legal considerations in fertility preservation”. International Journal of Gynecology and Obstetrics 115 (2011): 11-15.
88. Condorelli M and Demeestere I. “Challenges of fertility preservation in non-oncological diseases”. Acta Obstetricia et Gynecologica Scandinavica5 (2019): 638-646.
89. De Ziegler D., et al. “Risk and safety management in infertility and assisted reproductive technology (ART): from the doctor's office to the ART procedure”. Fertility and Sterility6 (2013): 1509-1517.
90. Anchan RM., et al. “Gestational carriers: A viable alternative for women with medical contraindications to pregnancy”. Open Journal of Obstetrics and Gynecology 5B (2013): 24-31.
91. Alteri A., et al. “Elective egg freezing without medical indications”. Acta Obstetricia et Gynecologica Scandinavica 5 (2019): 647-652.
92. Oktay K., et al. “Robot-assisted orthotopic and heterotopic ovarian tissue transplantation techniques: surgical advances since our first success in 2000”. Fertility and Sterility3 (2019): 604-606.
93. Update on fertility preservation from the Barcelona International Society for Fertility Preservation-ESHRE-ASRM 2015 expert meeting: indications, results and future perspectives. Francisca Martinez, on behalf of the International Society for Fertility Preservation-ESHRE-ASRM Expert Working Group. Fertility and Sterility3 (2019): 407-415.

Citation

Citation: Batiza Resendiz Víctor Alfonso., et al. “Fertility Preservation: Opinion of a Group of Experts". Acta Scientific Women's Health 5.4 (2023): 98-128.

Copyright

Copyright: © 2023 Batiza Resendiz Víctor Alfonso., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.